<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">7547213</article-id><article-id pub-id-type="pmc">2034051</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Comparative efficacy of a single oral dose of ondansetron and of buspirone against cisplatin-induced emesis in cancer patients.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Alfieri</surname><given-names>A. B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cubeddu</surname><given-names>L. X.</given-names></name></contrib></contrib-group><aff>Department of Pharmacology, School of Pharmacy, Central University of Venezuela, Caracas.</aff><pub-date pub-type="ppub"><month>10</month><year>1995</year></pub-date><volume>72</volume><issue>4</issue><fpage>1013</fpage><lpage>1015</lpage><abstract><p>Buspirone, an agonist of the 5-HT1A subtype of serotonin receptors, has shown antiemetic activity in animal models. However, in cancer patients treated with cisplatin, ondansetron, given either i.v. (one 8-mg dose 30 min after cisplatin) or orally (one 16-mg dose at the end of cisplatin infusion) was superior (P &#x0003c; 0.001) to buspirone (60 mg p.o. at the end of cisplatin and 60 mg p.o., 30 min later), in all parameters of antiemetic efficacy. These results are in favour of 5-HT3 receptors, but against the participation of 5-HT1A receptors in acute emesis associated with cisplatin chemotherapy.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00044-0213.tif" xlink:title="scanned-page" xlink:role="1013" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00044-0214.tif" xlink:title="scanned-page" xlink:role="1014" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00044-0215.tif" xlink:title="scanned-page" xlink:role="1015" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

